# Discovery of Isotucaresol derivatives as adjuvants for vaccines testing in a SARS-CoV-2 vaccine model

> **NIH NIH N01** · INIMMUNE CORPORATION · 2021 · $598,808

## Abstract

The long-term goal of the program is the commercial development of synthetic mimetics of novel saponin adjuvants that can be produces as single chemical entities on a large scale, are chemically more stable than current saponin adjuvants.

## Key facts

- **NIH application ID:** 10488957
- **Project number:** 75N93021C00054-0-9999-1
- **Recipient organization:** INIMMUNE CORPORATION
- **Principal Investigator:** OMER RASHEED
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $598,808
- **Award type:** —
- **Project period:** 2021-09-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10488957

## Citation

> US National Institutes of Health, RePORTER application 10488957, Discovery of Isotucaresol derivatives as adjuvants for vaccines testing in a SARS-CoV-2 vaccine model (75N93021C00054-0-9999-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10488957. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*